Anxiety disorders affect nearly one in five U.S. adults in a given year, yet some people do not achieve adequate relief through standard treatments (National Institute of Mental Health [NIMH], n.d.). If you’ve tried multiple SSRIs, worked through cognitive behavioral therapy, and still find that a persistent layer of anxiety shapes your daily life in ways that limit your work, relationships, and sense of ease, you’re not out of options. At Mindful Infusions in Salt Lake City, we treat patients across the Wasatch Front who are living with anxiety that has resisted conventional approaches, and IV ketamine therapy, used off-label for psychiatric conditions, is one of the options we discuss and offer.
Living in Utah brings its own relationship with anxiety. The demands of an outdoor-oriented, high-achievement culture along the Wasatch Front, where weekends in the Cottonwood Canyons and Wasatch Mountain trails can feel as much like social currency as personal pleasure, can make anxiety feel even more isolating when it prevents you from participating fully. At Mindful Infusions, we understand that context, and we offer care that takes your full life, not just your symptom list, into account.
The Regulatory Landscape for Ketamine and Anxiety
The first thing to understand, and the thing we say clearly in every consultation, is that IV ketamine is not FDA-approved for anxiety disorders. Ketamine is FDA-approved as an anesthetic. SPRAVATO®, or esketamine nasal spray, has separate FDA approval for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior when used with an oral antidepressant. It is not approved for anxiety (Rosenbaum et al., 2024; U.S. Food and Drug Administration [FDA], 2025).
When we offer IV ketamine at Mindful Infusions for anxiety conditions, that constitutes off-label use, and we disclose this directly. Off-label use does not mean there is no supporting research. It means the formal FDA approval process has not been completed for that indication. What the evidence does show is worth understanding.
What the Evidence Shows for Ketamine in Anxiety
The clinical research on ketamine for anxiety disorders is growing, though it remains more limited than the evidence base for treatment-resistant depression. Ketamine is an NMDA receptor antagonist that affects glutamatergic signaling, which is one reason researchers are studying its potential role in anxiety disorders (Rosenbaum et al., 2024; Tully et al., 2022).
A small randomized, double-blind, placebo-controlled crossover trial found that a single IV ketamine infusion produced greater reductions in clinician-rated social anxiety symptoms than placebo (Taylor et al., 2018). Systematic reviews and meta-analyses suggest ketamine may reduce anxiety symptoms across several clinical settings, but they also emphasize the need for larger, longer-term studies focused specifically on anxiety disorders (Hartland et al., 2023; Tully et al., 2022).
For patients whose anxiety and depression are intertwined, this overlap has practical relevance. Our blog post on anxiety treatment options in Salt Lake City explores how different approaches compare for patients navigating this intersection. Some patients describe a quieting of the baseline threat-readiness that makes chronic anxiety so exhausting. Results vary by individual, and we do not guarantee any specific outcome.
Who Is Most Likely to Benefit
We are direct with patients about where ketamine stands in the anxiety treatment hierarchy. If you have recently been diagnosed with an anxiety disorder and have not yet tried established treatments such as SSRIs, SNRIs, or structured cognitive behavioral therapy, ketamine may not be the appropriate starting point. These approaches remain important parts of anxiety care (NIMH, n.d.).
We ask about your treatment history in detail during our evaluation, not to create barriers, but because it helps us give you an honest answer about whether ketamine is likely to be useful for your specific situation.
We’ve observed at Mindful Infusions that patients who come to us for anxiety frequently describe a multi-year journey with medications and therapy, real work that produced partial gains and a residual core of anxiety that has not shifted. Many describe anxiety as intertwined with depression, sleep disruption, and physical tension that persists despite their best efforts. For some of these patients, ketamine may offer another option to consider after conventional approaches have not provided enough relief.
Practical Considerations for Utah Patients
Because anxiety is an off-label indication, insurance coverage for IV ketamine may be limited, and many patients pay out of pocket. We discuss pricing transparently during the consultation so you can make an informed decision. We also recognize that cost looks different for someone who has spent years in a state of functional limitation. The ongoing costs of anxiety, including professional impairment, relationship strain, and avoidance patterns, are real, even when they are harder to calculate than an invoice.
Fear about the infusion experience is particularly common among anxious patients, which makes intuitive sense. The idea of a dissociative medical procedure can feel like the opposite of reassuring when you already live with heightened threat sensitivity. That is why we walk you through what to expect at your first ketamine clinic visit, including possible perceptual and dissociative effects, the timeline, what we monitor, and how to communicate with us if anything feels uncomfortable. The environment is calm, private, and unhurried. Our ketamine FAQs can also help answer common questions before your consultation.
A full course of treatment typically involves a series of infusions, and scheduling is individualized based on your treatment plan and response. You will need a driver for each session. Additional infusions may be discussed for patients who respond, based on their individual needs.
We also encourage ongoing engagement with a ketamine-assisted psychotherapy provider. The idea of a post-treatment neuroplasticity window is promising, but it remains an area of active study. Continuing behavioral and cognitive work during this period may help patients make use of the insights and momentum that emerge through treatment (Wilkinson et al., 2019). Discuss all of these factors with your provider before beginning treatment.
Key Takeaways
- IV ketamine for anxiety is an off-label use. It is not FDA-approved for anxiety disorders, and we communicate this directly in every consultation.
- Ketamine acts through NMDA receptors in the glutamate system, a mechanism distinct from standard monoamine-targeting medications (Rosenbaum et al., 2024).
- Clinical research has found anxiety symptom reduction following ketamine in some settings, including social anxiety disorder, but results vary and more research is needed (Taylor et al., 2018; Tully et al., 2022).
- Ketamine for anxiety is generally considered after established approaches such as SSRIs, SNRIs, and cognitive behavioral therapy have not provided adequate relief.
- We prioritize thorough preparation and a supportive environment so you know what to expect before treatment begins.
If anxiety has been shaping your life in ways that medications and therapy have not fully resolved, our team at Mindful Infusions is ready to have an honest conversation about what else might be possible. We serve patients throughout Salt Lake City and the Wasatch Front. To schedule a consultation, call (385) 299-0473 or visit Mindful Infusions.
References
Hartland, H., Mahdavi, K., Jelen, L. A., Strawbridge, R., Young, A. H., & Alexander, L. (2023). A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects. Journal of Psychopharmacology, 37(8), 764–774. https://doi.org/10.1177/02698811231161627
National Institute of Mental Health. (n.d.). Any anxiety disorder. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder
Rosenbaum, S. B., Gupta, V., Patel, P., & Palacios, J. L. (2024). Ketamine. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470357
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018). Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. Neuropsychopharmacology, 43(2), 325–333. https://doi.org/10.1038/npp.2017.194
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. (2022). Ketamine treatment for refractory anxiety: A systematic review. British Journal of Clinical Pharmacology, 88(10), 4412–4426. https://doi.org/10.1111/bcp.15374
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Wilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019). Leveraging neuroplasticity to enhance adaptive learning: The potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression. Biological Psychiatry, 85(6), 454–465. https://doi.org/10.1016/j.biopsych.2018.09.004
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine infusion therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. SPRAVATO® is FDA-approved for specific indications; IV ketamine for psychiatric conditions is used off-label. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.